GRFS (Grifols) Current Deferred Revenue: $0 Mil (As of Mar. 2026)


GRFS Grifols SA GRFS
82 GF Score
Price $7.26
GF Value $8.91
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Grifols Current Deferred Revenue?

Grifols GRFS -0.48% 82 Current Deferred Revenue is $0 Mil as of Mar. 2026. GuruFocus rates GRFS with a GF Score™ of 82/100 and a GF Value™ of $8.91 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Grifols's current deferred revenue for the quarter that ended in Mar. 2026 was $0 Mil.

Grifols Current Deferred Revenue Related Terms

Grifols Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Grifols's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grifols Current Deferred Revenue Chart

Grifols Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 49.20 0.00 42.74 45.03 39.81

Grifols Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 39.81 0.00
GRFS
82GF Score
Grifols SA GRFS
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $0 Mil mean?
Grifols (GRFS) has a Current Deferred Revenue of $0 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Grifols and its competitors.
Is Grifols' Current Deferred Revenue too high?
Grifols' current Current Deferred Revenue is $0 Mil. Overall, Grifols has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grifols' Current Deferred Revenue compare to LLY and JNJ?
Grifols' Current Deferred Revenue of $0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Drug Manufacturers company?
A good Current Deferred Revenue depends on the Drug Manufacturers industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Grifols and its competitors. Grifols's current Current Deferred Revenue is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Based on GuruFocus' analysis, Grifols (GRFS) is currently considered Modestly Undervalued. The stock's GF Value™ is $8.91, compared to a current price of $7.26 — trading 18.6% below its estimated fair value. The current Current Deferred Revenue is $0 Mil. Grifols' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Grifols (GRFS), the current Current Deferred Revenue is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Grifols (GRFS) Overvalued in 2026?

Based on GuruFocus' analysis, Grifols stock appears to be undervalued. The current stock price of $7.26 is trading 18.6% below its estimated GF Value™ of $8.91. GuruFocus considers Grifols to be Modestly Undervalued.

Key valuation signals for GRFS:

  • Current Deferred Revenue: $0 Mil
  • GF Value™: $8.91 vs. price of $7.26 (18.6% below fair value)
  • GF Score™: 82/100 with 7 warning signs

No single metric tells the full story. See the GRFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Grifols Business Description

Address Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
82GF Score

Get the complete analysis for GRFS

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.26
Price
$8.91
GF Value